Drug Trial Radar · NCT07791654
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight or Obesity
Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Aug 23, 2025
Primary completion
Mar 21, 2026
Study completion Mar 21, 2026
Sponsor
- Lead sponsor
- Shanghai Minwei Biotechnology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blind, placebo-controlled phase II study conducted in China. It aims to evaluate the efficacy and safety of MWN109 injection in non-diabetic participants with overweight or obesity. A total of 120 participants were enrolled in the study. All participants were randomly assigned using stratified block randomization by gender (male or female) and allocated to 4 treatment groups at a 1:1:1:1 ratio, with approximately 30 participants in each group. Each treatment group will reach the This study consists of a screening period of up to 2 weeks, a treatment period of 24 weeks, and a follow-up period of 2 weeks, totaling 28 weeks. The primary endpoint is the percentage change in body weight compared to the baseline after 24 weeks of drug administration. The secondary endpoints include the proportions of participants with a body weight reduction of ≥5%, ≥10%, ≥15%, and ≥20% relative to the baseline after 24 weeks of treatment, as well as the change in waist circumference relative to the baseline.target dose through dose titration.
Conditions
- Overweight , Obesity
Interventions
MWN109 1Drug
Administered SC, QW, 24 weeks
MWN109 2Drug
Administered SC, QW, 24 weeks
MWN109 3Drug
Administered SC, QW, 24 weeks
PlaceboDrug
Administered SC, QW, 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in body weight compared to baseline after 24 weeks of drug administrationTime frame: Baseline, Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.